Global Plasmid DNA Manufacturing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Plasmid DNA Manufacturing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

A circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. The unique property of self-replication makes it unique and available to use in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology.

Market Overview:

The latest research study on the global Plasmid DNA Manufacturing market finds that the global Plasmid DNA Manufacturing market reached a value of USD 956.93 million in 2022. It’s expected that the market will achieve USD 1681.52 million by 2028, exhibiting a CAGR of 9.85% during the forecast period.

Pharmaceutical companies cooperate with contract plasmid manufacturers to speed up the production of nucleic acid-based biopharmaceuticals-including Covid-19 vaccine and gene therapy-based drugs. Plasmids are essential for nucleic acid-based vaccines and gene therapy. Efficient plasmid production is an important factor in the large-scale production of several Covid-19 vaccines.
AGC, a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that its biopharmaceutical CDMO subsidiary, AGC Biologics, has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC's Heidelberg, Germany facility.
Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, signed an agreement with INOVIO Pharmaceuticals Inc. to manufacture the COVID-19 DNA vaccine candidate, INO-4800.
Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and Scancell Holdings plc (Scancell), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announced that they have entered into a collaboration for Cobra to manufacture Scan cell's COVID-19 vaccine. The epidemic has promoted the development of the Plasmid DNA Manufacturing industry.

The rapid growth of the biopharmaceutical industry

In the past two years, the number of researched new drugs has increased greatly, and many drugs have been authorized for commercial sale. Due to this growth, contract manufacturers providing GMP-grade plasmids are trying to keep up with the increasing demand. The recent epidemic situation has aggravated this problem, because many candidate vaccines are being developed, including DNA-based vaccines and mRNA-based vaccines, in which plasmid DNA is needed as the starting material of mRNA transcription in vitro. The continuous growth of downstream demand will promote the development of the Plasmid DNA Manufacturing industry.

The emergence of substitutes

As an alternative method of plasmid DNA production, Touchlight, a London-based biotech company, developed a synthetic DNA manufacturing method using an in vitro dual enzyme process. With its ability to amplify any circular DNA template by using the proprietary in vitro enzymatic rolling circle method, doggy bone DNA solves most problems of traditional fermentation, which is superior to traditional methods in speed, scalability, and safety, but it is still economically and efficiently. Torchlight's proprietary DNA manufacturing platform can realize scalable DNA production within a few weeks, instead of the months required for plasmid DNA production by the traditional E.coli fermentation method. The emergence of substitutes will pose certain challenges to the Plasmid DNA Manufacturing industry.

Region Overview:

North America dominated the Plasmid DNA Manufacturing market in 2021, with a market share of 45.97%.

Company Overview:

Aldevron is one of the major players operating in the Plasmid DNA Manufacturing market, holding a share of 41.35% in 2021.

Aldevron

Aldevron has grown into a world-class service organization specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe.

Kaneka Eurogentec

Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, that specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health, and approved by the US FDA for the commercial manufacturing of a biologic for the US market.

Segmentation Overview:


By type, GMP Grade Plasmid DNA segment accounted for the largest share of market in 2021.

Application Overview:

By application, the Gene Therapy segment occupied the biggest share from 2017 to 2022.

DNA Vaccines

DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.

Gene Therapy

Gene Therapy focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material.

Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system.

Key Companies in the global Plasmid DNA Manufacturing market covered in Chapter 3:

AGC Biologics
Waisman Biomanufacturing
TriLink Biotechnologies
AnGes, Inc.
VGXI, Inc.
Nature Technology Corporation
Aldevron
Kaneka

In Chapter 4 and Chapter 14.2, on the basis of types, the Plasmid DNA Manufacturing market from 2018 to 2029 is primarily split into:

High Quality (HQ) Plasmid DNA
GMP Grade Plasmid DNA
Non-GMP Grade Plasmid DNA

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Plasmid DNA Manufacturing market from 2018 to 2029 covers:

DNA Vaccines
Gene Therapy
Immunotherapy

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)